StockNews.AI
ALXO
StockNews.AI
210 days

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

1. ALX will present ASPEN-06 trial data on January 23, 2025. 2. Evorpacept targets HER2-positive gastric cancer and shows promising results. 3. Oral presentation at ASCO GI will highlight key findings. 4. Company leadership will discuss data in a following webcast for investors.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive trial results can encourage investor confidence, similar to past successful data announcements.

How important is it?

Trial outcomes can significantly impact ALXO's market perception and future funding.

Why Short Term?

Upcoming data release may lead to immediate stock movement, akin to previous earnings reports.

Related Companies

ALXO
Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the company will host a virtual event on Thursday, January 23, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from the ASPEN-06 Phase 2 clinical trial evaluating the company’s investigational CD47-blocker evorpacept in patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The ASPEN-06 data will be featured in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) earlier the same day. 2025 ASCO GI Presentation DetailsTitle: Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC).Abstract Number: 332Presenter: Kohei Shitara, M.D., Director of the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in JapanPresentation Date and Time: Thursday, January 23, 9:15 a.m. – 10:00 a.m. PTSession Information: Rapid Oral Abstract Session A: Cancers of the Esophagus and StomachLocation: Level 2 Ballroom Company Conference Call and Webcast InformationDuring the virtual company conference call and webcast event for investors, ALX company leadership will review the updated ASPEN-06 data. The event will be webcast live and a replay will be available after the call by visiting the “Investors” section of ALX Oncology’s website and selecting “Events and Presentations.”  Date & Time: Thursday, January 23, 1:00 p.m. PT/4:00 p.m. ETWebcast Access: https://edge.media-server.com/mmc/p/ipy66o44About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Related News